Nanovi submits cancer biomarker for marketing approval in the US
Danish firm Nanovi has submitted its leading product, a biomarker for cancer therapies, for approval on the world’s biggest cancer market, where it has the potential to break new ground, says CEO Jesper Boysen.
by albert rønning-andersson, translated by daniel pedersen
Danish medtech firm Nanovi, whose chair of the board is Ambu heir Simon Hesse Hoffmann, has reached one of the bigger milestones in its history, which began in 2012 when the company was spun out from the Technical University of Denmark, DTU.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
